At a glance
What is it—and why does it matter?
LL-37 is described as a human cathelicidin peptide that participates in the primary immune response.
Sources for this introduction: [1]
This published profile is a reference in progress. Findings retain their source context; missing topics are marked below.
What is it?
A molecule, not a product name.
Identity
LL-37 is described as a human cathelicidin peptide that participates in the primary immune response.
- Source records
- 3
- Independent studies
- 3
Evidence boundary: Applies only to the source-defined population, formulation, dose, and assessment period.
Exact passages, locators, and provenance
- supports · Source-backed record
“A member of the cathelicidin family of antimicrobial peptides.”
IUPHAR ligand commentary · General comments
iuphar-comments:5527:730a870b6d20:730a870b6d20 - supports · Source-backed record
“LL-37, a human cathelicidin involved in primary immune response”
Exposure to the antimicrobial peptides LL-37 and ATRA-1 induces a lipidome response in Staphylococcus aureus that alters membrane biophysical properties. · Abstract
pubmed:42303202:6b77d72127a7:6b77d72127a7 - supports · Source-backed record
“the antimicrobial peptide LL-37”
Responsive dual-layer hydrogel microneedles accelerate diabetic wound healing via antibacterial and enzyme cascade regulation. · Abstract
pubmed:42155356:2a4cf83d9bbb:2a4cf83d9bbb
How does it work?
Target, response, and disposition.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
What has been studied?
What the evidence says.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Risks and interactions
Risks, organized for scanning.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Products and regulatory status
Same ingredient. Different records.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Administration context
The practical clinical context.
This profile does not yet contain a published summary for this topic. This is a coverage gap, not evidence that no research exists.
Research status + gaps
What still needs better answers?
- No publishable claim yet for: administration, contraindication, effect, interaction, mechanism, regulatory, safety
- 34 compiled claim(s) withheld by automated assurance: assurance_score_below_0.58 (27), assurance_score_below_0.72 (6), current_regulatory_source_required (5), extraction_ambiguity (21), high_risk_requires_regulatory_or_two_independent_sources (7), no_direct_support (32)
These are the limits of this profile, not an exhaustive list of scientific uncertainties.
References + discovery
Open the records yourself.
- IUPHAR ligand commentary ↗
iuphar-comments · published 2026-08-27 · retrieved 2026-08-27T11:48:55Z
- Responsive dual-layer hydrogel microneedles accelerate diabetic wound healing via antibacterial and enzyme cascade regulation. ↗
pubmed · published 2026-10-01 · retrieved 2026-08-27T11:48:55Z
- Exposure to the antimicrobial peptides LL-37 and ATRA-1 induces a lipidome response in Staphylococcus aureus that alters membrane biophysical properties. ↗
pubmed · published 2026-10-01 · retrieved 2026-08-27T11:48:55Z
Publication history and provenance
Version 1 · Automated assessment · 2026-08-27T11:48:55Z
e2ef7b8126cb2f50b984387640edd56c1f6fd4261dbf9f4fe08de6f792a93cd8